Posted in | News | Optics and Photonics

Collaborative Agreement Focusing on Optical Packet Switching Technologies

Alcatel-Lucent and NTT today announced that they have signed a collaborative agreement focusing on optical packet switching technologies. The collaborative agreement was signed yesterday between Alcatel-Lucent's Bell Labs research organization and NTT's Photonics Labs in a private signing ceremony.

The continuing demand for innovations in packet transport networks are driven by several factors including: the emergence of very-high bandwidth subscribers, notably with FTTx deployments on a large scale; new reduced power consumption and footprint specifications; and low latency applications such as storage area network (SAN) or grid computing. Through this agreement Alcatel-Lucent Bell Labs and NTT Photonics will cooperate in investigations on optical packet switching technology, including transport multi-protocol label switching (T-MPLS), the initial version of MPLS Transport. Specific terms and conditions of the agreement were not disclosed.

"We are pleased to collaborate with Alcatel-Lucent on this project - one that represents a significant occasion to combine our well-proven research capabilities with Bell Labs' market-leading expertise in optical networking to raise the bar of technology innovation and benefit end-users," said Yoshio Itaya, director of NTT science and core technology laboratory group.

"We are looking forward to taking the next step in Alcatel-Lucent's already close and successful research and development cooperation with NTT," said Jean-Luc Beylat, head of business partnerships at Alcatel-Lucent's Bell Labs. "As the demand for technology innovation continues to increase, this collaborative agreement is a powerful opportunity for two world class research organizations to collaborate in addressing the very complex challenges in the next generation of optical networks.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.